Therapy im Yasni Exposé von Guenter Kraus

The major goal of this contract is to use gene therapy to target essential genes of HIV-SIV in order to inhibit virus expression.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important component of antiretroviral therapy for HIV type-1 infected patients.

The present invention relates to methods and means for the evaluation of HIV treatment. In particular, molecular events at the HIV gag and protease proteins and their effect on therapeutic efficacy of drugs are determined The methods rely on providing HIV gag and protease nucleic acid material and evaluating a

Mark C. Leavitt, Mang Yu, Osamu Yamada, Günter Kraus, David Looney, Eric Poeschla, Flossie Wong-Staal. Human Gene Therapy. September 1994, 5(9): 1115- 1120. ...

Luc Geeraert, Günter Kraus, Roger J Pomerantz. The success of highly active antiretroviral therapy (HAART) for HIV-1 infection has sparked interest in ...

Guenter Kraus; Mechelen, Belgium 16:15 Challenges and Opportunities for Future HIV Therapeutics On behalf of Merck: Daria Hazuda; West Point, USA 16:30 Update on Gilead Anti-HIV ...

Design of novel highly efficient HIV based packaging systems for gene therapy - US Patent 6323019 from PatentStorm. By transducing cells with an HIV-1-MN molecular clone deleted in the major packaging sequence, a stable HIV-1 packaging cell line, .

Third International Workshop on HIV Persistence during Therapy ... Aylin Yilmaz. The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden ...